Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency

Victor W. Van Beusechem, Petra B. Van den Doel, Jacques Grill, Herbert M. Pinedo, Winald R. Gerritsen

Research output: Contribution to journalArticle

Abstract

Conditionally replicative adenoviruses (CRAds) hold promise as anticancer agents. Their potency depends on their replication efficiency in cancer cells and their capacity to destroy these cells by oncolysis. In this regard, a critical determinant is the capacity of CRAds to induce cell death at late stages of infection to release their progeny. One of the cell death pathways that are exploited by adenoviruses involves the tumor suppressor protein p53. Unfortunately, many cancer cells have a nonfunctional p53 pathway and thus do not effectively support CRAd-induced cell death. We hypothesized that restoration of the p53-dependent cell death pathway in cancer cells would promote CRAd-induced cell lysis. Exogenous expression of p53 in human cancer cells during adenovirus replication accelerated cell death by several days and augmented early virus progeny release. The p53-enhanced oncolysis occurred independent of E1A binding to pRb and independent of E3 functions. On the basis of these findings, we constructed a new CRAd, AdΔ24-p53. This virus expressed functional p53 while replicating in cancer cells. Most importantly, AdΔ24-p53 exhibited enhanced oncolytic potency on 80% of tested human cancer cell lines of various tissue origins and with different p53 status. CRAd potency was increased up to > 100-fold by p53 expression. We conclude that CRAds expressing p53 are promising new agents for more effective treatment of many human cancers.

Original languageEnglish (US)
Pages (from-to)6165-6171
Number of pages7
JournalCancer Research
Volume62
Issue number21
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Adenoviridae
Cell Death
Neoplasms
Virus Release
Tumor Suppressor Protein p53
Antineoplastic Agents
Viruses
Cell Line
Infection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Beusechem, V. W., Van den Doel, P. B., Grill, J., Pinedo, H. M., & Gerritsen, W. R. (2002). Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Research, 62(21), 6165-6171.

Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. / Van Beusechem, Victor W.; Van den Doel, Petra B.; Grill, Jacques; Pinedo, Herbert M.; Gerritsen, Winald R.

In: Cancer Research, Vol. 62, No. 21, 01.11.2002, p. 6165-6171.

Research output: Contribution to journalArticle

Van Beusechem, VW, Van den Doel, PB, Grill, J, Pinedo, HM & Gerritsen, WR 2002, 'Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency', Cancer Research, vol. 62, no. 21, pp. 6165-6171.
Van Beusechem VW, Van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Research. 2002 Nov 1;62(21):6165-6171.
Van Beusechem, Victor W. ; Van den Doel, Petra B. ; Grill, Jacques ; Pinedo, Herbert M. ; Gerritsen, Winald R. / Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. In: Cancer Research. 2002 ; Vol. 62, No. 21. pp. 6165-6171.
@article{91ca39efdef341779adb2c94f856bda6,
title = "Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency",
abstract = "Conditionally replicative adenoviruses (CRAds) hold promise as anticancer agents. Their potency depends on their replication efficiency in cancer cells and their capacity to destroy these cells by oncolysis. In this regard, a critical determinant is the capacity of CRAds to induce cell death at late stages of infection to release their progeny. One of the cell death pathways that are exploited by adenoviruses involves the tumor suppressor protein p53. Unfortunately, many cancer cells have a nonfunctional p53 pathway and thus do not effectively support CRAd-induced cell death. We hypothesized that restoration of the p53-dependent cell death pathway in cancer cells would promote CRAd-induced cell lysis. Exogenous expression of p53 in human cancer cells during adenovirus replication accelerated cell death by several days and augmented early virus progeny release. The p53-enhanced oncolysis occurred independent of E1A binding to pRb and independent of E3 functions. On the basis of these findings, we constructed a new CRAd, AdΔ24-p53. This virus expressed functional p53 while replicating in cancer cells. Most importantly, AdΔ24-p53 exhibited enhanced oncolytic potency on 80{\%} of tested human cancer cell lines of various tissue origins and with different p53 status. CRAd potency was increased up to > 100-fold by p53 expression. We conclude that CRAds expressing p53 are promising new agents for more effective treatment of many human cancers.",
author = "{Van Beusechem}, {Victor W.} and {Van den Doel}, {Petra B.} and Jacques Grill and Pinedo, {Herbert M.} and Gerritsen, {Winald R.}",
year = "2002",
month = "11",
day = "1",
language = "English (US)",
volume = "62",
pages = "6165--6171",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency

AU - Van Beusechem, Victor W.

AU - Van den Doel, Petra B.

AU - Grill, Jacques

AU - Pinedo, Herbert M.

AU - Gerritsen, Winald R.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Conditionally replicative adenoviruses (CRAds) hold promise as anticancer agents. Their potency depends on their replication efficiency in cancer cells and their capacity to destroy these cells by oncolysis. In this regard, a critical determinant is the capacity of CRAds to induce cell death at late stages of infection to release their progeny. One of the cell death pathways that are exploited by adenoviruses involves the tumor suppressor protein p53. Unfortunately, many cancer cells have a nonfunctional p53 pathway and thus do not effectively support CRAd-induced cell death. We hypothesized that restoration of the p53-dependent cell death pathway in cancer cells would promote CRAd-induced cell lysis. Exogenous expression of p53 in human cancer cells during adenovirus replication accelerated cell death by several days and augmented early virus progeny release. The p53-enhanced oncolysis occurred independent of E1A binding to pRb and independent of E3 functions. On the basis of these findings, we constructed a new CRAd, AdΔ24-p53. This virus expressed functional p53 while replicating in cancer cells. Most importantly, AdΔ24-p53 exhibited enhanced oncolytic potency on 80% of tested human cancer cell lines of various tissue origins and with different p53 status. CRAd potency was increased up to > 100-fold by p53 expression. We conclude that CRAds expressing p53 are promising new agents for more effective treatment of many human cancers.

AB - Conditionally replicative adenoviruses (CRAds) hold promise as anticancer agents. Their potency depends on their replication efficiency in cancer cells and their capacity to destroy these cells by oncolysis. In this regard, a critical determinant is the capacity of CRAds to induce cell death at late stages of infection to release their progeny. One of the cell death pathways that are exploited by adenoviruses involves the tumor suppressor protein p53. Unfortunately, many cancer cells have a nonfunctional p53 pathway and thus do not effectively support CRAd-induced cell death. We hypothesized that restoration of the p53-dependent cell death pathway in cancer cells would promote CRAd-induced cell lysis. Exogenous expression of p53 in human cancer cells during adenovirus replication accelerated cell death by several days and augmented early virus progeny release. The p53-enhanced oncolysis occurred independent of E1A binding to pRb and independent of E3 functions. On the basis of these findings, we constructed a new CRAd, AdΔ24-p53. This virus expressed functional p53 while replicating in cancer cells. Most importantly, AdΔ24-p53 exhibited enhanced oncolytic potency on 80% of tested human cancer cell lines of various tissue origins and with different p53 status. CRAd potency was increased up to > 100-fold by p53 expression. We conclude that CRAds expressing p53 are promising new agents for more effective treatment of many human cancers.

UR - http://www.scopus.com/inward/record.url?scp=0036830143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036830143&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 6165

EP - 6171

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -